表紙
市場調查報告書

人體微生物的全球市場:成長機會、市場預測 (∼2023年)

Growth Opportunities in Human Microbiome Market, Forecast to 2023

出版商 Frost & Sullivan 商品編碼 916767
出版日期 內容資訊 英文 88 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
人體微生物的全球市場:成長機會、市場預測 (∼2023年) Growth Opportunities in Human Microbiome Market, Forecast to 2023
出版日期: 2019年11月06日內容資訊: 英文 88 Pages
簡介

用了本報告提供人體微生物的OTC產品、治療藥、診斷藥的市場調查,彙整市場定義和概要,市場趨勢、市場成長的各種影響因素分析,主要課題,相關法律方案,收益預測,開發平台(管線)趨勢,競爭環境,主要企業的配合措施,成長機會、成功策略分析等資料。

執行儀表板

市場概要

  • 市場定義
  • 微生物治療藥:主要的類型
  • 主要舉措
  • 推動因素與阻礙
  • 推動因素與阻礙:影響製圖

市場動態

  • 主要課題
  • 對微生物的引進帶來很大的影響的領域
  • 法律規章方案分析:OTC部門
  • 法律規章方案分析:微生物醫藥品

成長環境:人體微生物市場

  • 市場工程評估
  • 預測的前提條件
  • 收益預測
  • 收益預測:各部門
  • 開發平台分析
  • 關注的微生物醫藥品

競爭環境

  • 供應商 生態系統
  • 關注的企業:Enterome Bioscience
  • 關注的企業:Chr. Hansen
  • 關注的企業:Seres Therapeutics
  • 關注的企業:Viome
  • 其他的關注企業:微生物治療藥
  • 其他的關注企業:微生物診斷藥
  • 大醫藥品經營者的支出分析
  • 授權契約分析
  • 主要企業:著重領域、候補藥的開發階段

願景方案

  • 從宏觀到微觀願景
  • 未來趨勢

成長管道

  • 成長桿

成長機會、策略 - 實行、建議:願景、策略

  • 成長機會:微生物為基礎的癌症免疫治療藥
  • 成長機會:微生物搭配診斷的個人化醫療

成長機會、策略 - 實行、建議:品牌、需求

  • 成長機會:健康、DTCMT的資料收益化
  • 成長機會:微生物 (OTC產品、醫藥品) 受託製造
  • 成長機會矩陣
  • 人體微生物企業的焦點地區
  • 未來的主要的治療領域
  • 人體微生物企業的策略性必要條件

總論

附錄

目錄
Product Code: MECA-55

Strategic Collaborations and Stakeholder Awareness Along with Clear Paths to Commercialization will Play a Key Role for Success in the Human Microbiome Market

Interest in the microbiome as a science and industry has exploded over the past decade. Innovations are happening across 3 significant categories for human health benefits: microbiome-based therapeutics, over-the-counter (OTC) dietary supplements, and self-diagnostics/screening. The OTC market is the largest because of the lack of precise regulation, but the importance of therapeutic and diagnostic products is rapidly increasing with more research substantiating the potential of microbiome-based therapy. Diagnostic applications of the microbiome include the diagnosis of infections and monitoring of microbial components related to non-communicable, chronic diseases.

The effect of next-generation sequencing (NGS) and the disruptive response to genomics has resulted in the development of novel, biomarker-based diagnostics and screening tests that only detect microbiome interactions or presence in humans. These are either direct-to-consumer products for more robust evaluations.

Because microbiome-based therapies constitute an entirely new therapeutic category, there is much uncertainty about the best paths to commercialization The United States is expected to have a faster adoption due to higher interest and awareness generated in this field by the Food and Drug Administration (FDA). One of the critical challenges in microbiome research is deciding whether a particular change in the microbiota is accountable for a specific condition, or if it is a side effect. The complexity of the microbiome and the fact that each person has a distinct one makes it extremely difficult to determine cause-effect relationships.

The global demand for more effective medicines and healthier nutrition will continue to drive the development of microbiomic products. Advancements in genomic sequencing and computer algorithms are expected to create both medicines and therapeutics based on individual microbiomes for better outcomes and healthier lives that will prevent or minimize diseases.

Research Highlights:

This study highlights the growth opportunities, visioning scenarios, innovative business models/use cases, competitive landscape, and key drivers and restraints, along with a revenue forecast for the human microbiome market.

Key Issues Addressed:

  • What is the market size and growth forecast for the human microbiome segments?
  • Who are the key competitors in this market? How does the competitive landscape look like?
  • What are the key growth opportunities for existing companies and new entrants in this market?
  • What changes to the business model are required from companies to cater to changes in market conditions?
  • How is the human microbiome market evolving? What are the key partnerships and collaborations in this industry?
  • What are the strategic imperatives for human microbiome industry participants?

Table of Contents

Executive Dashboard

  • Purpose of this Experiential Study
  • 5-Step Process to Transformational Growth
  • Market Scope and Segmentation
  • Key Questions this Study will Answer
  • Market Snapshot
  • Market Engineering Measurements-Human Microbiome Market
  • Key Findings
  • Frost & Sullivan's Big Market Prospects
  • Major Growth Opportunities
  • Microbiome Ecosystem-Industry Convergence Map
  • Strategic Imperatives for Growth

Market Overview

  • Market Definition
  • Key Types of Microbiome Therapeutics
  • Understanding Human Microbiome-Major Initiatives
  • Understanding Human Microbiome-Major Initiatives (continued)
  • Drivers and Restraints
  • Impact Mapping of Drivers and Restraints

Market Dynamics

  • Key Challenges in the Human Microbiome Market
  • Areas That Will Highly Impact Microbiome Adoption
  • Regulatory Scenario Assessment-OTC Segment
  • Regulatory Scenario Assessment-OTC Segment (continued)
  • Regulatory Scenario Assessment-Microbiome-based Drugs
  • Regulatory Scenario Assessment-Microbiome-based Drugs (continued)
  • Regulatory Scenario Assessment-Microbiome-based Drugs (continued)

Growth Environment-Human Microbiome Market

  • Market Engineering Measurements-Human Microbiome Market
  • Forecast Assumptions
  • Revenue Forecast
  • Forecast Discussions
  • Revenue Forecast by Segment
  • Microbiome-based Drugs-Pipeline Analysis
  • Microbiome-based Drugs-Pipeline Analysis (continued)
  • Microbiome-based Drugs-Pipeline Analysis (continued)
  • Key Microbiome-based Drugs to Watch

Competitive Landscape

  • Vendor Ecosystem
  • Key Companies to Watch-Enterome Bioscience
  • Key Companies to Watch-Chr. Hansen
  • Key Companies to Watch-Seres Therapeutics
  • Key Companies to Watch-Viome
  • Other Companies to Watch-Microbiome Therapeutics
  • Other Companies to Watch-Microbiome Diagnostics
  • Analysis of Big Pharma Spend on Human Microbiome Market
  • Analysis of Big Pharma Spend on Human Microbiome Market (continued)
  • Key Licensing Deals Analysis
  • Key Licensing Deals Analysis (continued)
  • Key Licensing Deals Analysis (continued)
  • Key Companies by Therapeutic Area of Focus and Stage of Microbiome Therapeutic Candidate

Visioning Scenarios

  • Human Microbiome Market-Macro to Micro Visioning
  • Key Future Trends in the Human Microbiome Market

Growth Pipeline

  • Levers for Growth

Growth Opportunities, Strategies-Implementation and Recommendation: Vision and Strategy

  • Growth Opportunity 1-Microbiome-based Cancer Immunotherapies
  • Growth Opportunity 1-Microbiome-based Cancer Immunotherapies (continued)
  • Growth Opportunity 1-Microbiome-based Cancer Immunotherapies (continued)
  • Growth Opportunity 1-Microbiome-based Cancer Immunotherapies (continued)
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics (continued)
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics (continued)
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics (continued)
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics (continued)

Growth Opportunities, Strategies-Implementation and Recommendation: Brand and Demand

  • Growth Opportunity 3-Wellness and Data Monetization Through DTCMT
  • Growth Opportunity 3-Wellness and Data Monetization Through DTCMT (continued)
  • Growth Opportunity 4-Microbiome (OTC and Therapeutic) Contract Manufacturing
  • Growth Opportunity 4-Microbiome (OTC and Therapeutic) Contract Manufacturing (continued)
  • Growth Opportunity Matrix
  • Focus Geographies for Human Microbiome Companies
  • Key Therapeutic Areas to Look Out for in Future
  • Strategic Imperatives for Human Microbiome Companies

The Last Word

  • 3 Big Predictions
  • Legal Disclaimer

Appendix

  • Research Till Date Has Identified Broadly 9 Therapy Areas Which Includes Multiple Chronic Diseases
  • List of Exhibits
  • List of Exhibits (continued)
Back to Top